Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

Al-Inany, Hesham; Youssef, Mohamed; Aboulghar, Mohamed; Broekmans, Frank J.; Sterrenburg, Monique; Smit, Janine G.; Abou‐Setta, Ahmed M

doi:10.1002/14651858.cd001750.pub3

Cited by 241 publications

(204 citation statements)

References 79 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…They concluded that there was no evidence of a statistically significant difference in rates of livebirths (9 RCTs; odds ratio (OR) 0.86, 95 % CI 0.69 to 1.08) [26]. Similarly, in the present study, no differences were observed in CPR between three protocols (16/110 14.5 %, 15/96 15.6 %, 5/34 14.7 %, respectively, p>0.05 )…”

Section: Discussioncontrasting

confidence: 44%

Anti-Müllerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age

Şahmay

Öncül

Tüten

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To investigate whether serum anti-müllerian hormone (AMH), follicle stimulating hormone (FSH), or antral follicle count (AFC) are predictive for clinical pregnancy in women who underwent IVF cycles at the age of 35 and older Methods A total of 240 consecutive women who underwent IVF cycles at the age of 35 and older were enrolled in this crsoss-sectional study. Pregnant and nonpregnant women were compared. Results The median AMH level of pregnant women was higher than non-pregnant women [3.20 (0.63-9.60) vs 1.15 (0.01-14.90) ng/ml, p<0.001]. On logistic regression analysis, AMH was an independent predictor of clinical pregnancy rate (CPR) (OR 1.353; 95 % CI 1.141-1.605; P<0.001). After controlling for the other independent variables (the number of retrieved oocytes, AFC and age), the significant association between AMH and clinical pregnancy rate remained strong (OR 1.677; 95 % CI 1.216-2.311; p=0.002) on multivariate logistic regression analysis. Conclusions AMH is an effective measure of quantitative ovarian reserve and it can predict ovarian response to controlled stimulation for advanced age women. The CPR tends to increase as AMH increases.

show abstract

Section: Discussioncontrasting

confidence: 44%

Anti-Müllerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age

Şahmay

Öncül

Tüten

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…The widespread use of GnRH antagonist co-treatment for primary prevention of OHSS has been, until now, the single most effective method in preventing OHSS, halving the risk of severe OHSS without hindering clinical outcomes [36]. However, OHSS still occurs in current clinical practice [14] and its overall importance increases with the steady worldwide proliferation of IVF.…”

Section: Discussionmentioning

confidence: 99%

Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition

Santos‐Ribeiro

Polyzos

Stouffs

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose We report on the results of the whole-genome analysis performed in a patient who developed severe ovarian hyperstimulation syndrome (OHSS) following gonadotropinreleasing hormone (GnRH) agonist triggering in a Bfreeze-allp rotocol.Methods A 30-year-old patient with polycystic ovary syndrome who developed severe early-onset OHSS with clinical ascites, and slight renal and hepatic dysfunction was admitted for monitoring and treatment with cabergoline and intravenous albumin. Exome sequencing to assess for any known genetic predisposition for OHSS was performed.Results No known genetic variants associated with OHSS predisposition were found. Conclusions Case reports of severe OHSS following a Bfreeze-all^strategy are starting to arise, showing that OHSS has not been completely eliminated with this approach. Further studies should be conducted to confirm if such cases may be due to genetic predisposition or not.

show abstract

“…There are multiple trials demonstrating a reduction in OHSS by use of gonadotrophinreleasing hormone (GnRH) antagonists for ovulation suppression as compared to GnRH agonist control [8]. The most recent Cochrane meta-analysis incorporating data from 20…”

Section: Use Gonadotrophin-releasing Hormone Antagonistsmentioning

confidence: 99%

Prevention and management of ovarian hyperstimulation syndrome

Nelson

2017

Thrombosis Research

View full text Add to dashboard Cite

Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of ovarian stimulation. It is feasible to identify patients at risk, modify stimulation strategies to ameliorate risk, and initiate out-patient treatments that alter disease pathophysiology to reduce disease severity. Mitigation of OHSS risk and severity, through innovative approaches prior to treatment, during treatment and after treatment should now be the standard care. This review summarizes recent developments and provides recommendations on the prevention and treatment of OHSS.3

show abstract

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

Cited by 241 publications

References 79 publications

Anti-Müllerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age

Anti-Müllerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age

Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition

Prevention and management of ovarian hyperstimulation syndrome

Contact Info

Product

Resources

About